Natixis Astrazeneca PLC Transaction History

Natixis

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$69.91 - $75.81 $5.05 Million - $5.48 Million	72,248 Added 11377.64%	72,883 $5.22 Million
Q1 2023 May 12, 2023	SELL	$63.15 - $71.6 $253,484 - $287,402	-4,014 Reduced 86.34%	635 $44,000
Q4 2022 Feb 24, 2023	BUY	$54.21 - $70.44 $252,022 - $327,475	4,649 New	4,649 $315,000
Q3 2021 Nov 12, 2021	SELL	$55.56 - $60.79 $41.7 Million - $45.6 Million	-750,051 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$48.42 - $60.18 $8.71 Million - $10.8 Million	179,920 Added 31.56%	750,051 $44.9 Million
Q1 2021 May 14, 2021	BUY	$47.16 - $54.44 $23.5 Million - $27.1 Million	498,244 Added 693.09%	570,131 $28.4 Million
Q4 2020 Feb 12, 2021	BUY	$48.52 - $58.02 $3.49 Million - $4.17 Million	71,887 New	71,887 $3.59 Million

1,340

476M

5.39M

3.75M

Ticker AZN
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 3,099,020,032
Market Cap $219B
Description
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

Stay updated on Natixis with notifications on news.